You are here : Home > Research Entities > Medicines and Healthcare Technologies

Institute | Diagnosis and innovative treatment | Mass spectrometry | Biomarkers


Medicines and Healthcare Technologies

Published on 9 January 2018

Medicines and Healthcare Technologies Department of the Frédéric Joliot Institute for Life Sciences, directed by Christophe Junot, carries out research in Diagnostic and Therapeutic Innovation, in particular in the Molecular Innovation area, around four thematic axes :

  • conception of bioactive molecules and nano-objects for diagnostic and therapeutic purposes,
  • identification and validation of molecular biomarkers for early diagnosis, therapeutic decision support and follow-up of innovative therapies,
  • development of technologies and methodologies for the detection and / or monitoring of the in vivo becoming of bioactive molecules,
  • development of technologies and methodologies for the detection of molecular biomarkers.

Medicines and Healthcare Technologies Department is divided in three Units : Molecular labeling and bio-organic chemistry unit (SCBM), Pharmacology and Immunoanalysis unit (SPI) and Molecular engineering of proteins unit (SIMOPRO) whose Research Teams are based in Saclay. It is affiliated with two LabEx: the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT) and the Laboratory of Excellence in Chemistry of Multifunctional Molecular Architectures and Materials (CHARM3AT).


(click on image to enlarge)


To carry out their activities, researchers of Medicines and Healthcare Technologies Department have access to several research platforms, two of which certified IBiSA, within the Frédéric Joliot Institute for Life Sciences:

  • High-Throughput screening (certified IBiSA) : biological screening platform for high-throughput compound libraries,
  • Métabolome IDF (certified IBiSA): metabolomic platform. This platform is integrated in the National Infrastructure in Biology and Health (INBS) MetaboHUB, financed by the Programme of Investments for the Future (PIA),
  • ProdIg : platform for the production of polyclonal and monoclonal antibodies,
  • SMArt-MS : platform dedicated to the absolute quantification of small molecules, drugs, metabolites and biomarkers in biological fluids,
  • L3 Laboratory : level 3 microbiological safety laboratory.